磷酸丝氨酸转氨酶1在非小细胞肺癌中的表达水平和预后关系分析
|
摘要
目的探讨磷酸丝氨酸转氨酶1(phosphoserine aminotransferase 1,PSAT1)在非小细胞肺癌组织中的表达水平,并分析PSAT1表达与非小细胞肺癌预后的相关性。方法选择2013年12月—2015年10月确诊的非小细胞肺癌患者89例为观察组,同期25例肺良性病变患者为对照组。分别采用实时荧光定量PCR和免疫组织化学法检测和比较两组PSAT1 mRNA表达水平和蛋白阳性表达率;并分析PSAT1表达与患者病理特征的关系。结果观察组PSAT1 mRNA和蛋白阳性表达率显著高于对照组(P<0.05)。PSAT1蛋白表达与肿瘤分化程度、TNM分期以及是否淋巴结转移有相关性(P<0.05);而与患者的性别、年龄和肿瘤大小无相关性(P>0.05)。结论 PSAT1在非小细胞肺癌组织中呈过表达状态,检测PSAT1的水平对预测非小细胞肺癌进程及患者预后有重要意义。
Objective To investigate expression level of phosphoserine aminotransferase 1( PSAT1) in nonsmall-cell lung cancer( NSCLC),and to analyze the relationship between PSAT1 protein and prognosis in NSCLC patients. Methods A total of 89 NSCLC patients during December 2013 and October 2015 were selected as observation group,and 25 patients with benign lung lesion at the same period were chosen as control group. Real-time fluorescent quantitation polymerase chain reaction( PCR) and immunohistochemistry method were respectively used to detect and compare expression level of PSAT1 mRNA and positive expression rate in two groups. The relationship between PSAT1 expression and clinicopathological characteristics was analyzed. Results Expression level of PSAT1 mRNA and positive expression rate in observation group were significantly higher than those in control group( P < 0. 05). Expression level of PSAT1 was correlated with differentiation degree,tumour node metastases( TNM) stage and lymph node metastasis( P <0. 05),but it was not correlated with gender,age or tumor size( P > 0. 05). Conclusion PSAT1 shows overexpression in NSCLC tissues. Detection of PSAT1 level is important for predicting NSCLC development and prognosis of patients.
Objective To investigate expression level of phosphoserine aminotransferase 1( PSAT1) in nonsmall-cell lung cancer( NSCLC),and to analyze the relationship between PSAT1 protein and prognosis in NSCLC patients. Methods A total of 89 NSCLC patients during December 2013 and October 2015 were selected as observation group,and 25 patients with benign lung lesion at the same period were chosen as control group. Real-time fluorescent quantitation polymerase chain reaction( PCR) and immunohistochemistry method were respectively used to detect and compare expression level of PSAT1 mRNA and positive expression rate in two groups. The relationship between PSAT1 expression and clinicopathological characteristics was analyzed. Results Expression level of PSAT1 mRNA and positive expression rate in observation group were significantly higher than those in control group( P < 0. 05). Expression level of PSAT1 was correlated with differentiation degree,tumour node metastases( TNM) stage and lymph node metastasis( P <0. 05),but it was not correlated with gender,age or tumor size( P > 0. 05). Conclusion PSAT1 shows overexpression in NSCLC tissues. Detection of PSAT1 level is important for predicting NSCLC development and prognosis of patients.
引文
[1]Rogasch J M,Apostolova I,Steffen I G,et al.Standardized visual reading of F18-FDG-PET in patients with nonsmall cell lung cancer scheduled for preoperative thoracic lymph node staging[J].Eur J Radiol,2016,85(8):1345-1350.
[2]Zappa C,Mousa S A.Non-small cell lung cancer:current treatment and future advances[J].Transl Lung Cancer Res,2016,5(3):288-300.
[3]徐宝宁,张磊,田大力.Rho A蛋白在人非小细胞肺癌中的表达及临床意义[J].中国医科大学学报,2014,43(8):710-713.
[4]Li Q,Zhan P,Yuan D,et al.Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer:a systematic review with meta-analysis[J].Transl Lung Cancer Res,2016,5(3):258-264.
[5]Yu J,Xiao F,Guo Y,et al.Hepatic phosphoserine aminotransferase 1 regulates insulin sensitivity in mice via tribbles homolog 3[J].Diabetes,2015,64(5):1591-1602.
[6]Battula P,Dubnovitsky A P,Papageorgiou A C.Structural basis of L-phosphoserine binding to Bacillus alcalophilus phosphoserine aminotransferase[J].Acta Crystallogr D Biol Crystallogr,2013,69(Pt 5):804-811.
[7]Liu B,Jia Y,Cao Y,et al.Overexpression of phosphoserine aminotransferase 1(PSAT1)predicts poor prognosis and associates with tumor progression in human esophageal squamous cell carcinoma[J].Cell Physiol Biochem,2016,39(1):395-406.
[8]Uyterlinde W.Overcoming toxicity-challenges in chemoradiation for non-small cell lung cancer[J].Transl Lung Cancer Res,2016,5(3):239-243.
[9]Nishino M,Hoang M P,Della Pelle P,et al.Napsin A/p40 antibody cocktail for subtyping non-small cell lung carcinoma on cytology and small biopsy specimens[J].Cancer Cytopathol,2016,124(7):472-484.
[10]李冬霞,张慧,蔡松旺.p21活化激酶4在非小细胞肺癌中的表达及其临床意义[J].中国病理生理杂志,2015,31(11):1956-1960.
[11]Ma L H,Li G,Zhang H W,et al.The effect of nonsmall cell lung cancer histology on survival as measured by the graded prognostic assessment in patients with brain metastases treated by hypofractionated stereotactic radiotherapy[J].Radiat Oncol,2016,11:92.
[12]Wang D,Lin Y,Gao B,et al.Reduced expression of FADS1 predicts worse prognosis in non-small-cell lung cancer[J].J Cancer,2016,7(10):1226-1232.
[13]曲卓慧,王跃辉,龚晶,等.晚期非小细胞肺癌患者预后相关因素分析[J].临床荟萃,2016,31(5):547-550.
[14]李芳.肺癌患者外周血中期因子水平表达与预后的关系研究[J].中国医药科学,2017,7(5):155-157,164.
[15]Yan S,Jiang H,Fang S,et al.MicroRNA-340 inhibits esophageal cancer cell growth and invasion by targeting phosphoserine aminotransferase 1[J].Cell Physiol Biochem,2015,37(1):375-386.
[16]Liao K M,Chao T B,Tian Y F,et al.Overexpression of the PSAT1 gene in nasopharyngeal carcinoma is an indicator of poor prognosis[J].J Cancer,2016,7(9):1088-1094.
[17]Yang Y,Wu J,Cai J,et al.PSAT1 regulates cyclin D1degradation and sustains proliferation of non-small cell lung cancer cells[J].Int J Cancer,2015,136(4):E39-50.
[2]Zappa C,Mousa S A.Non-small cell lung cancer:current treatment and future advances[J].Transl Lung Cancer Res,2016,5(3):288-300.
[3]徐宝宁,张磊,田大力.Rho A蛋白在人非小细胞肺癌中的表达及临床意义[J].中国医科大学学报,2014,43(8):710-713.
[4]Li Q,Zhan P,Yuan D,et al.Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer:a systematic review with meta-analysis[J].Transl Lung Cancer Res,2016,5(3):258-264.
[5]Yu J,Xiao F,Guo Y,et al.Hepatic phosphoserine aminotransferase 1 regulates insulin sensitivity in mice via tribbles homolog 3[J].Diabetes,2015,64(5):1591-1602.
[6]Battula P,Dubnovitsky A P,Papageorgiou A C.Structural basis of L-phosphoserine binding to Bacillus alcalophilus phosphoserine aminotransferase[J].Acta Crystallogr D Biol Crystallogr,2013,69(Pt 5):804-811.
[7]Liu B,Jia Y,Cao Y,et al.Overexpression of phosphoserine aminotransferase 1(PSAT1)predicts poor prognosis and associates with tumor progression in human esophageal squamous cell carcinoma[J].Cell Physiol Biochem,2016,39(1):395-406.
[8]Uyterlinde W.Overcoming toxicity-challenges in chemoradiation for non-small cell lung cancer[J].Transl Lung Cancer Res,2016,5(3):239-243.
[9]Nishino M,Hoang M P,Della Pelle P,et al.Napsin A/p40 antibody cocktail for subtyping non-small cell lung carcinoma on cytology and small biopsy specimens[J].Cancer Cytopathol,2016,124(7):472-484.
[10]李冬霞,张慧,蔡松旺.p21活化激酶4在非小细胞肺癌中的表达及其临床意义[J].中国病理生理杂志,2015,31(11):1956-1960.
[11]Ma L H,Li G,Zhang H W,et al.The effect of nonsmall cell lung cancer histology on survival as measured by the graded prognostic assessment in patients with brain metastases treated by hypofractionated stereotactic radiotherapy[J].Radiat Oncol,2016,11:92.
[12]Wang D,Lin Y,Gao B,et al.Reduced expression of FADS1 predicts worse prognosis in non-small-cell lung cancer[J].J Cancer,2016,7(10):1226-1232.
[13]曲卓慧,王跃辉,龚晶,等.晚期非小细胞肺癌患者预后相关因素分析[J].临床荟萃,2016,31(5):547-550.
[14]李芳.肺癌患者外周血中期因子水平表达与预后的关系研究[J].中国医药科学,2017,7(5):155-157,164.
[15]Yan S,Jiang H,Fang S,et al.MicroRNA-340 inhibits esophageal cancer cell growth and invasion by targeting phosphoserine aminotransferase 1[J].Cell Physiol Biochem,2015,37(1):375-386.
[16]Liao K M,Chao T B,Tian Y F,et al.Overexpression of the PSAT1 gene in nasopharyngeal carcinoma is an indicator of poor prognosis[J].J Cancer,2016,7(9):1088-1094.
[17]Yang Y,Wu J,Cai J,et al.PSAT1 regulates cyclin D1degradation and sustains proliferation of non-small cell lung cancer cells[J].Int J Cancer,2015,136(4):E39-50.